Silver Nitrate
drugOn this page
Also known as Argenti nitrasArgentum nitricumAvocaCausticNSC-135800Silver nit causticToughened silver nitrate
Summary
Silver Nitrate (CHEMBL177367) is an approved small-molecule astringent (ATC D08AL01); indicated across 5 conditions including dental caries and chlamydia trachomatis infectious disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: D08AL01
- Indications: 5 conditions
- Clinical trials: 14
- Chemistry: 169.873 Da · AgNO3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL177367 |
| Name | Silver Nitrate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 24470 |
| ChEBI | CHEBI:32130 |
| ATC | D08AL01 |
| Molecular formula | AgNO3 |
| Molecular weight | 169.873 |
| InChIKey | SQGYOTSLMSWVJD-UHFFFAOYSA-N |
SMILES: [N+](=O)([O-])[O-].[Ag+]
IUPAC name: silver nitrate
Pharmacological roles (ChEBI): astringent.
Other ChEBI roles (chemical / environmental): NMR chemical shift reference compound.
Also known as: Argenti nitras, Argentum nitricum, Avoca, Caustic, NSC-135800, Silver nit caustic, Silver nitrate, Toughened silver nitrate, silver Nitrate, SILVER NITRATE
Patent coverage: 80,593 distinct patent families (169,387 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 169,336 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| dental caries | 3 | MONDO:0005276 | EFO:0003819 |
| chlamydia trachomatis infectious disease | 3 | MONDO:0005701 | EFO:0007205 |
| chronic kidney disease | 3 | MONDO:0005300 | MONDO:0024327 |
| burn | 2 | MONDO:0043519 | EFO:0009516 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 14.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 4 |
| PHASE4 | 3 |
| PHASE3 | 2 |
| Not specified | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02116608 | PHASE4 | COMPLETED | Treatment of Tracheostomy Granulomas |
| NCT02398539 | PHASE4 | UNKNOWN | Silver Nitrate Application and Topical Corticosteroids for Hypergranulation Tissue |
| NCT04560049 | PHASE4 | COMPLETED | Phenol and Silver Nitrate Application in Pilonidal Sinus |
| NCT06681194 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Silver Nitrate vs. Triamcinolone for Treatment of Hypergranulation Tissue |
| NCT01996930 | PHASE3 | COMPLETED | Steroid Impregnated Tape in the Treatment of Over-granulating Peritoneal Dialysis Exit Sites |
| NCT02519738 | PHASE3 | TERMINATED | Granulation Tissue Treatment: Silver Nitrate vs Kenalog vs Washcloth Abrasion |
| NCT01125124 | PHASE2 | UNKNOWN | Safety and Effectiveness Study for Pleurodesis With Silver Nitrate in Malignant Pleural Effusion |
| NCT01567215 | PHASE2 | COMPLETED | Treatment of Granuloma Umbilical in Newborn Babies |
| NCT03781908 | PHASE1/PHASE2 | UNKNOWN | Management of Malignant Pleural Effusion With Indwelling Pleural Catheter Versus Silver Nitrate Pleurodesis |
| NCT04248101 | PHASE2 | COMPLETED | Double Ligation and Topical Silver Nitrate |
| NCT06363539 | PHASE2 | COMPLETED | Silver Nitrate Versus Topical Steroid For Umbilical Granuloma |
| NCT02604134 | EARLY_PHASE1 | COMPLETED | Medical Management of Caries in the Primary Dentition Using Silver Nitrate |
| NCT06629558 | Not specified | RECRUITING | Bronchoscopic Lung Volume Reduction in Management of Localized Emphysema |
| NCT06836791 | Not specified | COMPLETED | Topical 15% Trichloroacetic Acid Versus Silver Nitrate Cauterization in the Management of Idiopathic Childhood Epistaxis: A Prospective Double-Blinded, Randomized Clinical Trial |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).